Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (2016 - 2025)

Protalix BioTherapeutics (PLX) has 15 years of Shares Outstanding data on record, last reported at $73.6 million in Q3 2024.

  • For Q3 2024, Shares Outstanding rose 0.93% year-over-year to $73.6 million; the TTM value through Sep 2024 reached $73.6 million, up 0.93%, while the annual FY2023 figure was $73.0 million, 35.62% up from the prior year.
  • Shares Outstanding reached $73.6 million in Q3 2024 per PLX's latest filing, roughly flat from $73.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $73.6 million in Q3 2024 and bottomed at $32.4 million in Q1 2020.
  • Average Shares Outstanding over 5 years is $53.3 million, with a median of $48.7 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: skyrocketed 134.3% in 2020, then grew 0.93% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $34.8 million in 2020, then soared by 31.04% to $45.6 million in 2021, then grew by 18.07% to $53.8 million in 2022, then surged by 35.62% to $73.0 million in 2023, then increased by 0.93% to $73.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $73.6 million in Q3 2024, $73.3 million in Q2 2024, and $73.1 million in Q1 2024.